Supplementary Material for: Upadacitinib Successfully Treated Dupilumab-Associated General

A 155.6 KB supplementary document from figshare, authored by figshare admin karger and last updated in May 2026. It details a single case report of a 6-year-old pediatric patient with atopic dermatitis who developed generalized pustular psoriasis following dupilumab therapy and was successfully treated with upadacitinib.

Use Cases

• Analyze the timeline of adverse reaction onset based on the detailed case chronology
• Study the efficacy of a specific treatment regimen based on the dosage and outcome described
• Review clinical decision-making for paradoxical psoriasis based on the therapeutic challenges outlined
• Benchmark treatment response timelines based on the one-month resolution period documented

Strengths

• Provides a detailed clinical timeline, including a 6-month follow-up period with no recurrence
• Includes specific dosage information (15 mg every other day) and patient age (6-year-old)
• Document is openly licensed under CC-BY-4.0

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data is limited to a single case report, representing a tiny dataset of 155.6 KB

Provenance

Source

figshare

Collection Method

Likely a clinical case report submitted as supplementary material.

Freshness

Last updated 2026-05-19 07:55:19; freshness should be verified